PPARD

ENSG00000112033
Target class
Nuclear receptor
Chromosome
6
Approved drugs
3
Clinical candidates (approved and in development)
14

Approved drugs
3
Clinical candidates (approved and in development)
14

Chemical probe available
Yes

Target name
PPARD
Gene name
Peroxisome proliferator activated receptor delta
Gene symbol
PPARD
Protein name
Peroxisome proliferator-activated receptor delta (PPAR-delta) (NUCI) (Nuclear hormone receptor 1) (NUC1) (Nuclear receptor subfamily 1 group C member 2) (Peroxisome proliferator-activated receptor beta) (PPAR-beta)

  • NUC1
  • NUCII
  • FAAR
  • NR1C2
  • PPARB

Gene biotype
Protein coding
Gene family
Peroxisome proliferator activated receptors
Target class
Nuclear receptor
Target type
Human gene

Tissues expressed in
54
Highest tissue expression
82.19
Tissue specificity (Gini)
0.229
Tissue specificity (tau)
0.621

KEGG gene identifiers
  • hsa:5467
Protein interaction confidence
0.790824
Protein interaction partners
34

  • R-HSA-200425
  • R-HSA-383280
  • R-HSA-5362517

End position
35428193
Start position
35342530
Chromosome
6
Strand
Forward

Ensembl gene ID
ENSG00000112033
HGNC ID
HGNC:9235
www.genenames.org
NCBI Gene ID
5467
UniProt ID
Q03181

  • Nucleus .

Publication evidence

Tissue specificity (tau)
0.621181
Expression inequality (Gini)
0.228771

Expression in transcripts per million

Thyroid
82.19
Esophagus - Mucosa
54.06
Ovary
53.03
Vagina
51.87
Brain - Cerebellum
46.72

Expression in transcripts per million

  • Thyroid82.19
  • Esophagus - Mucosa54.06
  • Ovary53.03
  • Vagina51.87
  • Brain - Cerebellum46.72
  • Prostate46.62
  • Cells - Cultured fibroblasts46.22
  • Spleen44.9
  • Lung44.76
  • Skin - Sun Exposed (Lower leg)43.5
  • Cervix - Endocervix43.47
  • Brain - Cerebellar Hemisphere42.24
  • Uterus41.06
  • Cervix - Ectocervix41.04
  • Nerve - Tibial40.83
  • Skin - Not Sun Exposed (Suprapubic)39.92
  • Bladder39.59
  • Fallopian Tube39.11
  • Pituitary37.95
  • Small Intestine - Terminal Ileum37.48
  • Brain - Cortex36.76
  • Colon - Sigmoid34.48
  • Brain - Frontal Cortex (BA9)34.37
  • Artery - Aorta34.25
  • Breast - Mammary Tissue30.5

And 29 more, listed on the interactive page.

  • Increased, Liver Steatosis

    Studies

    • cell-based
    Evidence source
    aopwiki.org

  • regulation of transcription factor activity

    • cell-based: ATG_PPRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
    • cell-based: ATG_PPARd_TRANS, is one of 30 assay component(s) measured or calculated from the ATG_TRANS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.
    • cell-based: TOX21_PPARd_BLA_Agonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.
    • cell-based: TOX21_PPARd_BLA_Antagonist_ratio is an assay readout measuring reporter gene via receptor activity and designed using inducible reporter (beta lactamase induction) detected with GAL4 b-lactamase reporter gene. The signal is derived from the ratio of cleaved (ch2) to uncleaved (ch1) reporter gene substrate used as the measure of target activity.
    • cell-based: ATG_PPRE_CIS, is one of 52 assay component(s) measured or calculated from the ATG_CIS assay. It is designed to make measurements of mRNA induction, a form of inducible reporter, as detected with fluorescence intensity signals by Reverse transcription polymerase chain reaction (RT-PCR) and Capillary electrophoresis technology.

    • HEK293T, cell line
    • HepG2, cell line
    Evidence source
    www.epa.gov

Related records

Trials (274)

Drugs (16)